General Information of Drug (ID: DM7XAV1)

Drug Name
JBH492 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7XAV1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CAP-100 DM1CVX3 Chronic lymphocytic leukaemia 2A82.0 Clinical trial [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 7 (CCR7) TT2GIDQ CCR7_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
2 Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. Cancer Immunol Immunother. 2022 Mar;71(3):627-636.